(firstQuint)CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors.

 This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced solid tumors.

 This study will consist of a dose escalation phase and a dose expansion phase.

.

 CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors@highlight

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors